phrykt

Veraxa Biotech AG - Post de-SPAC (VRXA): who owns it and who trades it

As of Oct 30, 2026, VRXA insiders reported 5 purchases worth $125K in the last 12 months. The largest buyer was Oliver Rolf Baumann (Director), with $75K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, VRXA insiders reported $125K of open-market purchases and $0 of sales.

Purchases, 12 months
$125K
5 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Oct 28, 2026
Filed Oct 29, 2026

Purchases and sales by month

$82.7K$82.7KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 28, 2026Marc GruningerDirectorPurchase9,133$1.00$9.1KForm 4
Oct 27, 2026Marc GruningerDirectorPurchase867$0.98$850Form 4
Oct 20, 2026Christoph Samuel ZieglerDirectorPurchase30,000$1.09$32.7KForm 4
Aug 27, 2026Oliver Rolf BaumannDirectorPurchase50,000$1.50$75KForm 4
Aug 27, 2026Christoph Rudiger AntzCEOPurchase5,000$1.53$7.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Oliver Rolf BaumannDirector$75K–Aug 27, 2026
Christoph Samuel ZieglerDirector$32.7K–Oct 20, 2026
Marc GruningerDirector$10K–Oct 28, 2026
Christoph Rudiger AntzChief Executive Officer, Director$7.7K–Aug 27, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VRXA short interest

91,222 VRXA shares are sold short. Over the last 10 reports the number of shares short went up 796%.

As of Oct 30, 2026, 91,222 VRXA shares were sold short, down 15.0% from the report before. At the average daily volume of 164,496 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short

91,222Jun 15Oct 30457,987

Days to cover

1.0Jun 15Oct 305.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202691,222–-15%164,4961.0
Oct 15, 2026107,383–-54%421,0311.0
Sep 30, 2026235,019–+12%51,4324.6
Sep 15, 2026209,727–+3%584,1121.0
Aug 31, 2026202,960–-46%204,0241.0
Aug 14, 2026378,219–-5%104,0633.6
Jul 31, 2026399,577–+66%322,0301.2
Jul 15, 2026240,554–+82%1.73M1.0
Jun 30, 2026131,851–+1196%548,3161.0
Jun 15, 202610,176––9,8111.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Questions about Veraxa Biotech AG - Post de-SPAC (VRXA) stock

Are VRXA insiders buying or selling?

In the last 12 months, VRXA insiders reported 5 open-market purchases worth $125K and no sales. The latest trade was on Oct 28, 2026. See every trade.

What is the short interest in VRXA?

As of Oct 30, 2026, 91,222 VRXA shares were sold short, down 15.0% from the report before. At the average daily volume of 164,496 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.